The Next Steps for Bevacizumab in Recurrent Cervical Cancer
Krishnansu S. Tewari, MD, from the University of California, Irvine, comments on the next steps for bevacizumab for recurrent cervical cancer.
Krishnansu S. Tewari, MD, a professor of obstetrics and gynecology at the University of California, Irvine, comments on the next steps for bevacizumab for recurrent cervical cancer.
Data from a phase III trial were presented at a plenary session at the 2013 American Society of Clinical Oncology (ASCO) Meeting. The manuscript will be reviewed by the Gynecologic Oncology Group (GOG) publications committee, CTEP, and the NCI. Then, Tewari says, it will be reviewed by the journal chosen by the researchers.
Clinical Pearls
As for the regulatory aspects of the trial, Tewari says that he is unsure of the timeline. Genentech and Roche, the manufacturers of the molecule, will discuss the possibility of approval with the FDA.
- Data were presented at the 2013 ASCO Meeting
- Manuscripts will be reviewed by the GOG publications committee, CTEP, and NCI
- Genentech and Roche, the manufacturers of the molecule, will discuss the possibility of approval with the FDA
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
